ARUP Launches First Clinical Spectral Flow Cytometry Assay for MRD Assessment in Multiple Myeloma

ARUP CLARISPECT™ Multiple Myeloma MRDPositive

AI Analysis

Summary

ARUP Laboratories launched ARUP CLARISPECT™, a new spectral flow cytometry assay for minimal residual disease (MRD) assessment in multiple myeloma patients, offering improved sensitivity and confidence in detecting neoplastic populations.

Importance:3/10

Sentiment:

0.50

diagnosticsflow cytometrymultiple myelomaMRD assessmentassay launch

Related Companies

$GCAN $TRAX

Read the original article

Published by PR Newswire Biotech on July 20, 2026 3:00 PM

Read Original